[HTML][HTML] Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
LS Otten, B Piet, MM van den Heuvel… - European …, 2022 - Eur Respiratory Soc
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
LS Otten, B Piet… - European …, 2022 - cris.maastrichtuniversity.nl
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.
LS Otten, B Piet, MM van den Heuvel… - European …, 2022 - search.ebscohost.com
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.
LS Otten, B Piet, MM van den Heuvel… - … Review: an Official …, 2022 - europepmc.org
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
[HTML][HTML] Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
LS Otten, B Piet, MM van den Heuvel… - European Respiratory …, 2022 - ncbi.nlm.nih.gov
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
LS Otten, B Piet, MM van den Heuvel… - … review: an official …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
[PDF][PDF] Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
LS Otten, B Piet, MM van den Heuvel, C Marzolini… - 2022 - serval.unil.ch
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
[PDF][PDF] Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
LS Otten, B Piet, MM van den Heuvel, C Marzolini… - 2022 - scholar.archive.org
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
[PDF][PDF] Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
LS Otten, B Piet, MM van den Heuvel, C Marzolini… - 2022 - repository.ubn.ru.nl
BACKGROUND: The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC)
patients is increased and often requires treatment or prophylaxis with direct oral …
patients is increased and often requires treatment or prophylaxis with direct oral …
[PDF][PDF] Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
LS Otten, B Piet, MM van den Heuvel, C Marzolini… - 2022 - serval.unil.ch
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …